F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma
Status:
RECRUITING
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open, Phase I clinical study to evaluate the safety and tolerability of F01 in subjects with relapsed/refractory non-Hodgkin lymphoma, and to determine MTD and/or RD.
Phase:
PHASE1
Details
Lead Sponsor:
Shanghai Simnova Biotechnology Co.,Ltd.
Collaborator:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology